Dual inhibition of <scp>AKT</scp> ‐m <scp>TOR</scp> and <scp>AR</scp> signaling by targeting <scp>HDAC</scp> 3 in <i> <scp>PTEN</scp> </i> ‐ or <i> <scp>SPOP</scp> </i> ‐mutated prostate cancer
EMBO molecular medicine